Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Malignant Lymphoma

  Free Subscription


Articles published in Haematologica

Retrieve available abstracts of 140 articles:
HTML format
Text format



Single Articles


    October 2019
  1. RECORD J, Sendel A, Kritikou JS, Kuznetsov NV, et al
    An intronic deletion in megakaryoblastic leukemia 1 is associated with hyperproliferation of B cells in triplets with Hodgkin lymphoma.
    Haematologica. 2019 Oct 3. pii: haematol.2019.216317.
    PubMed     Text format     Abstract available


    September 2019
  2. FERRERO S, Rossi D, Rinaldi A, Bruscaggin A, et al
    KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study.
    Haematologica. 2019 Sep 19. pii: haematol.2018.214056.
    PubMed     Text format     Abstract available


  3. TOWNSEND W, Pasikowska M, Yallop D, Phillips EH, et al
    The architecture of neoplastic follicles in follicular lymphoma; analysis of the relationship between the tumor and follicular helper T-cells.
    Haematologica. 2019 Sep 19. pii: haematol.2019.220160.
    PubMed     Text format     Abstract available


  4. DRIEUX F, Ruminy P, Abdel-Sater A, Lemonnier F, et al
    Defining the signatures of peripheral T-cell lymphoma, with a targeted 20-markers gene expression profiling assay (RT-MLPA).
    Haematologica. 2019 Sep 5. pii: haematol.2019.226647.
    PubMed     Text format     Abstract available


  5. EYRE TA, Djebbari F, Kirkwood AA, Collins GP, et al
    A systematic review of the efficacy of CNS prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era.
    Haematologica. 2019 Sep 5. pii: haematol.2019.229948.
    PubMed     Text format     Abstract available


    August 2019
  6. TEDESCHI A, Greil R, Demirkan F, Robak T, et al
    A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Haematologica. 2019 Aug 14. pii: haematol.2019.223743.
    PubMed     Text format    


  7. LI Z, Song Y, Zhang Y, Li C, et al
    Genomic and outcome analysis of adult T-cell lymphoblastic lymphoma.
    Haematologica. 2019 Aug 14. pii: haematol.2019.220863.
    PubMed     Text format    


  8. MIKA T, Ladigan S, Baraniskin A, Vangala D, et al
    Allogeneic hematopoietic stem cell transplantation for primary central nervous system lymphoma.
    Haematologica. 2019 Aug 8. pii: haematol.2019.227199.
    PubMed     Text format    


  9. TANAKA J, Tanaka N, Wang YH, Mistuhashi K, et al
    Phase I study of cellular therapy using ex vivo expanded NK cell from autologous peripheral blood mononuclear cells combined with rituximab-containing chemotherapy for relapsed CD20-positive malignant lymphoma patients.
    Haematologica. 2019 Aug 8. pii: haematol.2019.226696.
    PubMed     Text format    


  10. SCHIEPPATI F, Balzarini P, Fisogni S, Re A, et al
    An increase in MYC copy number has a progressive negative prognostic impact in patients with diffuse large B-cell and high-grade lymphoma, who may benefit of intensified treatment regimens.
    Haematologica. 2019 Aug 8. pii: haematol.2019.223891.
    PubMed     Text format     Abstract available


  11. NANN D, Bonzheim I, Muller I, Mankel B, et al
    Clonally related duodenal-type follicular lymphoma and in situ follicular neoplasia.
    Haematologica. 2019 Aug 1. pii: haematol.2019.226142.
    PubMed     Text format    


  12. BAILLY C, Carlier T, Berriolo-Riedinger A, Casasnovas O, et al
    Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project.
    Haematologica. 2019 Aug 1. pii: haematol.2019.223016.
    PubMed     Text format    


    July 2019
  13. FEDERMANN B, Frauenfeld L, Pertsch H, Borgmann V, et al
    Highly sensitive and specific in situ hybridization assay for quantification of SOX11 mRNA in mantle cell lymphoma reveals association of TP53 mutations with negative and low SOX11 expression.
    Haematologica. 2019 Jul 11. pii: haematol.2019.219543.
    PubMed     Text format     Abstract available


  14. ANDO M, Ando J, Yamazaki S, Ishii M, et al
    Long-term eradication of extranodal NK/T cell lymphoma, nasal type, by induced pluripotent stem cell-derived Epstein-Barr virus-specific rejuvenated T cells in vivo.
    Haematologica. 2019 Jul 11. pii: haematol.2019.223511.
    PubMed     Text format     Abstract available


  15. VIDAL-CRESPO A, Matas-Cespedes A, Rodriguez V, Rossi C, et al
    Daratumumab displays in vitro and in vivo anti-tumor activity in models of B cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens.
    Haematologica. 2019 Jul 11. pii: haematol.2018.211904.
    PubMed     Text format     Abstract available


  16. XIE S, Wei F, Sun YM, Gao YL, et al
    EZH2 inhibitors abrogate upregulation of trimethylation of H3K27 by CDK9 inhibitors and potentiate its activity against diffuse large B-cell lymphoma.
    Haematologica. 2019 Jul 9. pii: haematol.2019.222935.
    PubMed     Text format     Abstract available


    June 2019
  17. FALGAS A, Pallares V, Unzueta U, Cespedes MV, et al
    A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models.
    Haematologica. 2019 Jun 27. pii: haematol.2018.211490.
    PubMed     Text format     Abstract available


  18. MARTIN-CORTAZAR C, Chiodo Y, Jimenez-P R, Bernabe M, et al
    CDCA7 finely tunes cytoskeleton dynamics to promote lymphoma migration and invasion.
    Haematologica. 2019 Jun 20. pii: haematol.2018.215459.
    PubMed     Text format     Abstract available


  19. NOWAKOWSKI GS, Chiappella A, Witzig TE, Scott DW, et al
    Variable global distribution of cell-of-origin from the ROBUST phase 3 study in diffuse large B-cell lymphoma.
    Haematologica. 2019 Jun 20. pii: haematol.2019.220475.
    PubMed     Text format    


  20. HU T, Chong Y, Lu S, McGuinness M, et al
    RAC1/2 activation promotes FGFR1 driven leukemogenesis in stem cell leukemia/lymphoma syndrome.
    Haematologica. 2019 Jun 20. pii: haematol.2018.208058.
    PubMed     Text format    


  21. FLINSENBERG TWH, Tromedjo CC, Hu N, Liu Y, et al
    Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK cell effector function in patients with mantle cell lymphoma.
    Haematologica. 2019 Jun 6. pii: haematol.2019.220590.
    PubMed     Text format    


    May 2019
  22. VERMAAT JS, Somers SF, de Wreede LC, Kraan W, et al
    MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavourable prognosis.
    Haematologica. 2019 May 23. pii: haematol.2018.214122.
    PubMed     Text format     Abstract available


  23. MAURER B, Nivarthi H, Wingelhofer B, Pham HTT, et al
    High activation of STAT5A drives peripheral T-cell lymphoma and leukemia.
    Haematologica. 2019 May 23. pii: haematol.2019.216986.
    PubMed     Text format     Abstract available


  24. YUAN CT, Huang TC, Chuang CC, Chuang YK, et al
    Clonal sequence tracking reveals TET2-mutated extranodal NK/T-cell lymphoma disseminated independent of EB virus.
    Haematologica. 2019 May 16. pii: haematol.2018.215327.
    PubMed     Text format    


  25. WAGENER R, Bens S, Toprak UH, Seufert J, et al
    Cryptic insertion of MYC exons 2 and 3 into the IGH locus detected by whole genome sequencing in a case of MYC-negative Burkitt lymphoma.
    Haematologica. 2019 May 9. pii: haematol.2018.208140.
    PubMed     Text format    


  26. LIANG JH, Wang L, Zhu HY, Qian J, et al
    Dose-adjusted EPOCH regimen as first-line treatment for non-Hodgkin's lymphoma-associated hemophagocytic lymphohistiocytosis: a single-arm, open-label, phase 2 trial.
    Haematologica. 2019 May 9. pii: haematol.2019.220301.
    PubMed     Text format    


  27. PHILLIPS AA
    Response to the comment: "Identifying potential factors of variable response to mogamulizumab in adult T-cell leukemia/lymphoma between Japanese and other populations".
    Haematologica. 2019;104:e228.
    PubMed     Text format    


  28. JANAKIRAM M, Miljkovic MD
    Identifying potential factors of variable response to mogamulizumab in adult T-cell leukemia/lymphoma between Japanese and other populations.
    Haematologica. 2019;104:e227.
    PubMed     Text format    


  29. JOHNSON W, Mishra A, Binder A, Gru A, et al
    Mogamulizumab versus investigator choice in relapsed/refractory adult T-cell leukemia/lymphoma: all four one or none for all?
    Haematologica. 2019;104:864-867.
    PubMed     Text format    


    April 2019
  30. CASCIONE L, Rinaldi A, Bruscaggin A, Tarantelli C, et al
    Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses.
    Haematologica. 2019 Apr 24. pii: haematol.2018.214957.
    PubMed     Text format    


  31. SIBON D, Nguyen DP, Schmitz N, Suzuki R, et al
    ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients.
    Haematologica. 2019 Apr 19. pii: haematol.2018.213512.
    PubMed     Text format    


  32. COOK LBM, Demontis MA, Sagawe S, Witkover A, et al
    Molecular remissions are observed in chronic adult T cell leukemia/lymphoma in patients treated with mogamulizumab.
    Haematologica. 2019 Apr 19. pii: haematol.2019.219253.
    PubMed     Text format    


  33. BELLEI M, Federico M
    The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective International T-Cell Project.
    Haematologica. 2019;104:e178.
    PubMed     Text format    


  34. DREGER P
    Comment to "The outcome of peripheral T-cell lymphoma patients failing first-line therapy".
    Haematologica. 2019;104:e178.
    PubMed     Text format    


  35. KUMAR A, Ying Z, Alperovich A, Dogan A, et al
    Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma.
    Haematologica. 2019;104:e163-e166.
    PubMed     Text format    


    March 2019
  36. BARRANCO GI, Fernandez S, Ona R, Gonzalez-Rincon J, et al
    Branched clonal evolution: nodal follicular lymphoma and primary diffuse large B-cell lymphoma of the central nervous system.
    Haematologica. 2019 Mar 19. pii: haematol.2018.214981.
    PubMed     Text format    


  37. CASADEI B, Broccoli A, Stefoni V, Pellegrini C, et al
    PD-1 blockade as bridge to allogenic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series.
    Haematologica. 2019 Mar 19. pii: haematol.2019.215962.
    PubMed     Text format    


  38. ROSSI D, Spina V, Bruscaggin A, Gaidano G, et al
    Liquid biopsy in lymphoma.
    Haematologica. 2019 Mar 7. pii: haematol.2018.206177.
    PubMed     Text format    


  39. GRANAI M, Ambrosio MR, Akarca A, Mundo L, et al
    Role of Epstein Barr virus in transformation of follicular lymphoma to diffuse large B-cell lymphoma: a case report and review of the literature.
    Haematologica. 2019 Mar 7. pii: haematol.2018.215053.
    PubMed     Text format    


  40. STEEN CB, Leich E, Myklebust JH, Lockmer S, et al
    A clinico-molecular predictor identifies follicular lymphoma patients at risk of early transformation after first-line immunotherapy.
    Haematologica. 2019 Mar 7. pii: haematol.2018.209080.
    PubMed     Text format    


    February 2019
  41. LOVISA F, Binatti A, Coppe A, Primerano S, et al
    A high definition picture of key genes and pathways mutated in pediatric follicular lymphoma.
    Haematologica. 2019 Feb 28. pii: haematol.2018.211631.
    PubMed     Text format    


  42. D'AGARO T, Zucchetto A, Vit F, Bittolo T, et al
    A B-cell receptor-related gene signature predicts response to ibrutinib treatmeant in mantle cell lymphoma cell lines.
    Haematologica. 2019 Feb 28. pii: haematol.2018.212811.
    PubMed     Text format    


  43. GRAETZ D, Crews KR, Azzato EM, Singh RK, et al
    Leukemic presentation of ALK+ Anaplastic Large Cell Lymphoma with a novel partner, poly(A) binding protein cytoplasmic 1 (PABPC1), responding to single-agent crizotinib.
    Haematologica. 2019 Feb 28. pii: haematol.2018.215103.
    PubMed     Text format    


  44. HICKS SW, Tarantelli C, Wilhem A, Gaudio E, et al
    The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity than SAR3419 in CD19-positive lymphoma and leukemia models.
    Haematologica. 2019 Feb 7. pii: haematol.2018.211011.
    PubMed     Text format     Abstract available


  45. GONZALEZ-FARRE B, Ramis-Zaldivar JE, Salmeron-Villalobos J, Balague O, et al
    Burkitt-like lymphoma with 11q aberration: A germinal center derived lymphoma genetically unrelated to Burkitt lymphoma.
    Haematologica. 2019 Feb 7. pii: haematol.2018.207928.
    PubMed     Text format     Abstract available


    January 2019
  46. TARANTELLI C, Zhang L, Curti E, Gaudio E, et al
    The BTK inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents.
    Haematologica. 2019 Jan 24. pii: haematol.2018.214759.
    PubMed     Text format    


  47. TOROSSIAN A, Broin N, Frentzel J, Daugrois C, et al
    Blockade of crizotinib-induced BCL2 elevation in ALK-positive anaplastic large cell lymphoma triggers autophagy associated with cell death.
    Haematologica. 2019 Jan 24. pii: haematol.2017.181966.
    PubMed     Text format     Abstract available


  48. QDAISAT A, Al Soud R, Wu CC, Rojas Hernandez CM, et al
    Poor performance of D-Dimer in excluding venous thromboembolism among patients with lymphoma and leukemia.
    Haematologica. 2019 Jan 10. pii: haematol.2018.211466.
    PubMed     Text format    


  49. TAKEUCHI M, Miyoshi H, Asano N, Yoshida N, et al
    Human leukocyte antigen class II expression is a good prognostic factor of adult T-cell leukemia/lymphoma.
    Haematologica. 2019 Jan 10. pii: haematol.2018.205567.
    PubMed     Text format     Abstract available


  50. SILVA A, Bassim S, Sarkozy C, Mottok A, et al
    Convergence of risk prediction models in follicular lymphoma.
    Haematologica. 2019 Jan 3. pii: haematol.2018.209031.
    PubMed     Text format    


  51. SASSE S, Reddemann K, Diepstra A, Borchmann S, et al
    Programmed cell death protein1 (PD1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse after conventional chemotherapy and at relapse on anti-PD1 treatment.
    Haematologica. 2019;104:e45-e46.
    PubMed     Text format    


  52. TAYLOR JG, Clear A, Calaminici M, Gribben JG, et al
    Programmed cell death protein-1 (PD1) expression in the microenvironment of classical Hodgkin lymphoma is similar between favorable and adverse outcome and does not enrich over serial relapses with conventional chemotherapy.
    Haematologica. 2019;104:e42-e44.
    PubMed     Text format    


    December 2018
  53. QUALLS D, Abramson JS
    Advances in risk assessment and prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma.
    Haematologica. 2018 Dec 20. pii: haematol.2018.195834.
    PubMed     Text format     Abstract available


  54. BELHADJ M, Mansour D, Kaltenbach S, Deau-Fischer B, et al
    T-cell large granular lymphocyte leukemia transformation into aggressive T-cell lymphoma: a report of two cases with molecular characterization.
    Haematologica. 2018 Dec 20. pii: haematol.2018.205542.
    PubMed     Text format    


  55. PHILLIPS AA, Fields PA, Hermine O, Ramos JC, et al
    Mogamulizumab versus investigator choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma.
    Haematologica. 2018 Dec 20. pii: haematol.2018.205096.
    PubMed     Text format     Abstract available


  56. SEYMOUR JF, Marcus R, Davies A, Gallop-Evans E, et al
    Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression.
    Haematologica. 2018 Dec 20. pii: haematol.2018.209015.
    PubMed     Text format     Abstract available


  57. ARESU L, Ferraresso S, Marconato L, Cascione L, et al
    New molecular and therapeutic insights into canine diffuse large B cell lymphoma elucidates the role of the dog as a model for human disease.
    Haematologica. 2018 Dec 13. pii: haematol.2018.207027.
    PubMed     Text format    


  58. DELAGE L, Manzoni D, Quinquenet C, Fontaine J, et al
    Molecular analysis of a CD19 negative diffuse large B cell lymphoma.
    Haematologica. 2018 Dec 13. pii: haematol.2018.203521.
    PubMed     Text format    


  59. UCHIDA A, Isobe Y, Asano J, Uemura Y, et al
    Targeting BCL2 with venetoclax is a promising therapeutic strategy for "double-protein-expression" lymphoma with MYC and BCL2 rearrangements.
    Haematologica. 2018 Dec 6. pii: haematol.2018.204958.
    PubMed     Text format     Abstract available


    November 2018
  60. RULE S, Dreyling M, Goy A, Hess G, et al
    Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow-up from a pooled analysis.
    Haematologica. 2018 Nov 15. pii: haematol.2018.205229.
    PubMed     Text format    


    October 2018
  61. HAGENBEEK A, Mooij H, Zijlstra J, Lugtenburg P, et al
    Phase 1 dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: the Transplant BRaVE study.
    Haematologica. 2018 Oct 31. pii: haematol.2018.196899.
    PubMed     Text format    


  62. BURKHARD R, Keller I, Arambasic M, Juskevicius D, et al
    TIRAP p.R81C is a novel lymphoma risk variant which enhances cell proliferation via NF-kappaB mediated signaling in B-cells.
    Haematologica. 2018 Oct 31. pii: haematol.2018.201590.
    PubMed     Text format     Abstract available


  63. BERGMANN AK, Fataccioli V, Castellano G, Martin-Garcia N, et al
    DNA methylation profiling identifies candidate genes for the pathogenesis of hepatosplenic T-cell lymphoma.
    Haematologica. 2018 Oct 18. pii: haematol.2018.196196.
    PubMed     Text format    


  64. CASAGRANDE N, Borghese C, Visser L, Mongiat M, et al
    CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth.
    Haematologica. 2018 Oct 11. pii: haematol.2018.196725.
    PubMed     Text format     Abstract available


  65. EVRARD SM, Pericart S, Grand D, Amara N, et al
    Targeted next generation sequencing reveals high mutation frequency of CREBBP, BCL2 and KMT2D in high-grade B-cell lymphoma with MYC and BCL2 and /or BCL6 rearrangements.
    Haematologica. 2018 Oct 11. pii: haematol.2018.198572.
    PubMed     Text format    


    September 2018
  66. KUBOTA-TANAKA M, Osumi T, Miura S, Tsujimoto H, et al
    B-lymphoblastic lymphoma with the TCF3-PBX1 fusion gene.
    Haematologica. 2018 Sep 27. pii: haematol.2018.199885.
    PubMed     Text format    


  67. LEIVONEN SK, Pollari M, Bruck O, Pellinen T, et al
    T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma.
    Haematologica. 2018 Sep 20. pii: haematol.2018.200105.
    PubMed     Text format     Abstract available


  68. OCHI Y, Hiramoto N, Yoshizato T, Ono Y, et al
    Clonally related diffuse large B-cell lymphoma and interdigitating dendritic cell sarcoma sharing MYC translocation.
    Haematologica. 2018 Sep 20. pii: haematol.2018.193490.
    PubMed     Text format    


  69. SCHUHMACHER B, Bein J, Rausch T, Benes V, et al
    JUNB, DUSP2, SGK1, SOCS1 and CREBBP are frequently mutated in T-cell/histiocyte rich large B-cell lymphoma.
    Haematologica. 2018 Sep 13. pii: haematol.2018.203224.
    PubMed     Text format     Abstract available


  70. STRATI P, Fanale M, Oki Y, Turturro F, et al
    Rituximab with ABVD vs ABVD for advanced stage high-risk classical Hodgkin lymphoma: a randomized phase II study.
    Haematologica. 2018 Sep 6. pii: haematol.2018.199844.
    PubMed     Text format    


  71. EYRE TA, Walter HS, Iyengar S, Follows G, et al
    Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy.
    Haematologica. 2018 Sep 6. pii: haematol.2018.198812.
    PubMed     Text format    


    August 2018
  72. GRESSIN R, Daguindau N, Tempescul A, Moreau A, et al
    A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first line treatment of older patients with mantle cell lymphoma.
    Haematologica. 2018 Aug 31. pii: haematol.2018.191429.
    PubMed     Text format     Abstract available


  73. KINOSHITA S, Ishida T, Ito A, Narita T, et al
    Cyclin-dependent kinase 9 as a potential specific molecular target in NK cell leukemia/lymphoma.
    Haematologica. 2018 Aug 3. pii: haematol.2018.191395.
    PubMed     Text format     Abstract available


  74. MENSAH AA, Cascione L, Gaudio E, Tarantelli C, et al
    Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma.
    Haematologica. 2018 Aug 3. pii: haematol.2018.191684.
    PubMed     Text format     Abstract available


  75. SASSE S, Reddemann K, Diepstra A, Oschlies I, et al
    Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment.
    Haematologica. 2018 Aug 3. pii: haematol.2018.196279.
    PubMed     Text format    


  76. DE SMEDT R, Peirs S, Morscio J, Matthijssens F, et al
    Preclinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma.
    Haematologica. 2018 Aug 3. pii: haematol.2018.199257.
    PubMed     Text format    


  77. MELANI C, Roschewski M, Wilson WH
    End-of-treatment and serial PET imaging has prognostic value and clinical utility in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R - Response to Adams et al.
    Haematologica. 2018;103:e382.
    PubMed     Text format    


  78. ADAMS HJA, Kwee TC
    Unproven value of end-of-treatment and serial follow-up FDG-PET in primary mediastinal B-cell lymphoma.
    Haematologica. 2018;103:e380-e381.
    PubMed     Text format    


    July 2018
  79. POLLARI M, Bruck O, Pellinen T, Vahamurto P, et al
    PD-L1+ tumor-associated macrophages and PD-1+ tumor infiltrating lymphocytes predict survival in primary testicular lymphoma.
    Haematologica. 2018 Jul 19. pii: haematol.2018.197194.
    PubMed     Text format     Abstract available


  80. DE CHARETTE M, Houot R
    Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy.
    Haematologica. 2018 Jul 13. pii: haematol.2017.184192.
    PubMed     Text format     Abstract available


  81. VILLA D, Sehn LH, Aquino-Parsons C, Tonseth P, et al
    Interim PET-directed therapy in limited stage Hodgkin lymphoma initially treated with ABVD.
    Haematologica. 2018 Jul 12. pii: haematol.2018.196782.
    PubMed     Text format    


  82. ARAF S, Wang J, Ashton-Key M, Korfi K, et al
    Transmission of diffuse large B cell lymphoma by an allogeneic stem-cell transplant.
    Haematologica. 2018 Jul 5. pii: haematol.2018.196907.
    PubMed     Text format    


    June 2018
  83. AMBROSIO MR, Lazzi S, Lo Bello G, Santi R, et al
    MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients.
    Haematologica. 2018 Jun 28. pii: haematol.2018.195958.
    PubMed     Text format    


  84. RECASENS-ZORZO C, Cardesa-Salzmann T, Petazzi P, Ros-Blanco L, et al
    Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma.
    Haematologica. 2018 Jun 28. pii: haematol.2017.180505.
    PubMed     Text format     Abstract available


  85. EPSTEIN MM, Rosner B, Breen EC, Batista JL, et al
    Pre-diagnosis plasma immune markers and risk of non-Hodgkin lymphoma in two prospective cohort studies.
    Haematologica. 2018 Jun 21. pii: haematol.2017.183236.
    PubMed     Text format     Abstract available


  86. MCPHAIL ED, Maurer MJ, Macon WR, Feldman AL, et al
    Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements.
    Haematologica. 2018 Jun 14. pii: haematol.2018.190157.
    PubMed     Text format     Abstract available


  87. PEREZ-SALVIA M, Aldaba E, Vara Y, Fabre M, et al
    In vitro and in vivo activity of a new small-molecule inhibitor of HDAC6 in mantle cell lymphoma.
    Haematologica. 2018 Jun 7. pii: haematol.2018.189241.
    PubMed     Text format    


    May 2018
  88. ESKELUND CW, Albertsson-Lindblad A, Kolstad A, Laurell A, et al
    Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma.
    Haematologica. 2018 May 24. pii: haematol.2018.194399.
    PubMed     Text format    


  89. STORTI S, Spina M, Pesce EA, Salvi F, et al
    Rituximab plus Bendamustine as front line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin's lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi.
    Haematologica. 2018 May 10. pii: haematol.2017.186569.
    PubMed     Text format     Abstract available


  90. TRNENY M, Verhoef G, Dyer MJ, Yehuda DB, et al
    A Phase 2 multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy.
    Haematologica. 2018 May 10. pii: haematol.2017.168401.
    PubMed     Text format     Abstract available


  91. MELANI C, Advani R, Roschewski M, Walters KM, et al
    End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted-EPOCH-R: A paradigm shift in clinical decision making.
    Haematologica. 2018 May 10. pii: haematol.2018.192492.
    PubMed     Text format     Abstract available


    April 2018
  92. STRATI P, Chihara D, Oki Y, Fayad LE, et al
    A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.
    Haematologica. 2018 Apr 5. pii: haematol.2018.187617.
    PubMed     Text format    


  93. KUPPERS R
    CD83 in Hodgkin lymphoma.
    Haematologica. 2018;103:561-562.
    PubMed     Text format    


    March 2018
  94. BELLEI M, Foss FM, Shustov AR, Horwitz SM, et al
    The outcome of peripheral T-cell lymphoma patients failing first line therapy: a report from the prospective, international T-Cell project.
    Haematologica. 2018 Mar 29. pii: haematol.2017.186577.
    PubMed     Text format     Abstract available


  95. HORN H, Kohler C, Witzig R, Kreuz M, et al
    Gene expression profiling reveals a close relationship between follicular lymphoma grade 3A and 3B, but distinct profiles of follicular lymphoma grade 1 and 2.
    Haematologica. 2018 Mar 22. pii: haematol.2017.181024.
    PubMed     Text format     Abstract available


  96. ALIG S, Jurinovic V, Pastore A, Bararia D, et al
    Impact of age on genetics and treatment efficacy in follicular lymphoma.
    Haematologica. 2018 Mar 15. pii: haematol.2018.187773.
    PubMed     Text format    


  97. MAFFINI E, Anderson LD Jr., Sandmaier BM, Green DJ, et al
    Nonmyeloablative allogeneic hematopoietic cell transplantation for relapsed or refractory Waldenstrom macroglobulinemia: Evidence for a graft-versus-lymphoma effect.
    Haematologica. 2018 Mar 15. pii: haematol.2017.184176.
    PubMed     Text format    


  98. NIJLAND ML, Koens L, Pals ST, Berge IJMT, et al
    Clinicopathological characteristics of T-cell non-Hodgkin lymphoma arising in patients with immunodeficiencies: a single-center case series of 25 patients and a review of the literature.
    Haematologica. 2018;103:486-496.
    PubMed     Text format     Abstract available


  99. LEMONNIER F, Poullot E, Dupuy A, Couronne L, et al
    Loss of 5-hydroxymethylcytosine is a frequent event in peripheral T-cell lymphomas.
    Haematologica. 2018;103:e115-e118.
    PubMed     Text format    


  100. WANG X, Chen Z, Mishra AK, Silva A, et al
    Chemotherapy-induced differential cell cycle arrest in B-cell lymphomas affects their sensitivity to Wee1 inhibition.
    Haematologica. 2018;103:466-476.
    PubMed     Text format     Abstract available


    February 2018
  101. BOMBEN R, Ferrero S, D'Agaro T, Dal Bo M, et al
    A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the "Fondazione Italiana Linfomi" MCL-0208 trial.
    Haematologica. 2018 Feb 22. pii: haematol.2017.184325.
    PubMed     Text format     Abstract available


  102. BIRSEN R, Willems L, Pallud J, Blanc E, et al
    Efficacy and safety of high-dose etoposide cytarabine as consolidation following rituximab methotrexate temozolomide induction in newly diagnosed primary central nervous system lymphoma in immunocompetent patients.
    Haematologica. 2018 Feb 22. pii: haematol.2017.185843.
    PubMed     Text format    


  103. RIMSZA LM, Li H, Braziel RM, Spier CM, et al
    Impact of histologic grading on survival in the SWOG S0016 follicular lymphoma cohort.
    Haematologica. 2018 Feb 22. pii: haematol.2017.175059.
    PubMed     Text format     Abstract available


  104. SUEHARA Y, Sakata-Yanagimoto M, Hattori K, Nanmoku T, et al
    Liquid biopsy for the identification of intravascular large B-cell lymphoma.
    Haematologica. 2018 Feb 22. pii: haematol.2017.178830.
    PubMed     Text format     Abstract available


  105. ARVIDSSON G, Henriksson J, Sander B, Wright AP, et al
    Mixed-species RNAseq analysis of human lymphoma cells adhering to mouse stromal cells identifies a core gene set that is also differentially expressed in the lymph node microenvironment of mantle cell lymphoma and chronic lymphocytic leukemia patients
    Haematologica. 2018 Feb 15. pii: haematol.2017.182048.
    PubMed     Text format     Abstract available


  106. SCHOMMERS P, Gillor D, Hentrich M, Wyen C, et al
    Incidence and risk factors for relapses in HIV-associated non-Hodgkin-lymphoma as observed in the German HIV-related lymphoma cohort study.
    Haematologica. 2018 Feb 8. pii: haematol.2017.180893.
    PubMed     Text format     Abstract available


  107. SHALABI H, Kraft IL, Wang HW, Yuan CM, et al
    Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma.
    Haematologica. 2018 Feb 1. pii: haematol.2017.183459.
    PubMed     Text format     Abstract available


    January 2018
  108. FUJI S, Utsunomiya A, Inoue Y, Miyagi T, et al
    Outcomes of patients with relapsed aggressive adult T-cell leukemia-lymphoma: clinical effectiveness of anti-CCR4 antibody and allogeneic hematopoietic stem cell transplantation.
    Haematologica. 2018 Jan 25. pii: haematol.2017.184564.
    PubMed     Text format    


  109. LI Z, Ju X, Lee K, Clarke C, et al
    CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma.
    Haematologica. 2018 Jan 19. pii: haematol.2017.178384.
    PubMed     Text format     Abstract available


  110. VAN DEN NESTE E, Andre M, Gastinne T, Stamatoullas A, et al
    Phase II study of oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma.
    Haematologica. 2018 Jan 19. pii: haematol.2017.180554.
    PubMed     Text format     Abstract available


  111. JI MM, Huang YH, Huang JY, Wang ZF, et al
    Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified.
    Haematologica. 2018 Jan 5. pii: haematol.2017.182444.
    PubMed     Text format     Abstract available


    December 2017
  112. KNORR F, Damm-Welk C, Ruf S, Singh VK, et al
    Blood cytokine concentrations of pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma patients.
    Haematologica. 2017 Dec 14. pii: haematol.2017.177972.
    PubMed     Text format     Abstract available


  113. BOBILLO S, Abrisqueta P, Carpio C, Raheja P, et al
    Promising activity of selinexor in the treatment of a patient with refractory diffuse large B-cell lymphoma and central nervous system involvement.
    Haematologica. 2017 Dec 14. pii: haematol.2017.181636.
    PubMed     Text format    


  114. AUNER HW, Iacobelli S, Sbianchi G, Knol-Bout C, et al
    Melphalan 140mg/m2 or 200mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party.
    Haematologica. 2017 Dec 7. pii: haematol.2017.181339.
    PubMed     Text format     Abstract available


    November 2017
  115. TRACY SI, Habermann TM, Feldman AL, Maurer MJ, et al
    Outcomes among US patients with diffuse large B cell lymphoma are independent of tumor Epstein Barr virus positivity or immunosuppression.
    Haematologica. 2017 Nov 23. pii: haematol.2017.176511.
    PubMed     Text format     Abstract available


  116. COUTRE S, Tedeschi A, Robak T, Barr PM, et al
    Survival adjusting for crossover: phase 3 study of ibrutinib vs chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Haematologica. 2017 Nov 23. pii: haematol.2017.175380.
    PubMed     Text format    


  117. BOSCH M, Akhter A, Chen BE, Mansoor A, et al
    A bio-clinical prognostic model using MYC and BCL2 predicts outcome in relapsed/refractory diffuse large B-cell lymphoma.
    Haematologica. 2017 Nov 2. pii: haematol.2017.179309.
    PubMed     Text format     Abstract available


  118. NG SB, Chung TH, Kato S, Nakamura S, et al
    EBV-associated primary nodal T/NK-cell lymphoma shows distinct molecular signature and copy number changes.
    Haematologica. 2017 Nov 2. pii: haematol.2017.180430.
    PubMed     Text format     Abstract available


    October 2017
  119. RUDELIUS M, Rosenfeldt MT, Leich E, Rauert-Wunderlich H, et al
    Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment.
    Haematologica. 2017 Oct 27. pii: haematol.2017.177162.
    PubMed     Text format     Abstract available


  120. LANDMANN E, Burkhardt B, Zimmermann M, Meyer U, et al
    Results and conclusions of the European Intergroup EURO-LB02 Trial in children and adolescents with lymphoblastic lymphoma.
    Haematologica. 2017 Oct 5. pii: haematol.2015.139162.
    PubMed     Text format     Abstract available


    September 2017
  121. YOUNES A, Salles G, Martinelli G, Bociek RG, et al
    Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed and refractory non-Hodgkin lymphoma.
    Haematologica. 2017 Sep 29. pii: haematol.2017.169656.
    PubMed     Text format     Abstract available


  122. LUGTENBURG P, Avivi I, Berenschot H, Ilhan O, et al
    Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study.
    Haematologica. 2017 Sep 21. pii: haematol.2017.173583.
    PubMed     Text format     Abstract available


  123. EICHENAUER DA, Becker I, Monsef I, Chadwick N, et al
    Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: A systematic review and meta-analysis of randomized clinical trials.
    Haematologica. 2017 Sep 14. pii: haematol.2017.167478.
    PubMed     Text format     Abstract available


    August 2017
  124. OKI Y, Kelly KR, Flinn I, Patel MR, et al
    CUDC-907 in relapsed/refractory diffuse Large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase 1 trial.
    Haematologica. 2017 Aug 31. pii: haematol.2017.172882.
    PubMed     Text format     Abstract available


  125. VIDAL-CRESPO A, Rodriguez V, Matas-Cespedes A, Lee E, et al
    The BTK inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on the NF-kappaB mutational status.
    Haematologica. 2017 Aug 24. pii: haematol.2017.168930.
    PubMed     Text format    


  126. BROCCOLI A, Pellegrini C, Di Rocco A, Puccini B, et al
    Italian real life experience with brentuximab vedotin: results of a large observational study on 40 relapsed/refractory systemic anaplastic large cell lymphoma.
    Haematologica. 2017 Aug 3. pii: haematol.2017.171355.
    PubMed     Text format     Abstract available


    July 2017
  127. MONDELAERS V, Suciu S, De Moerloose B, Ferster A, et al
    Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951.
    Haematologica. 2017 Jul 27. pii: haematol.2017.165845.
    PubMed     Text format     Abstract available


  128. JALLADES L, Baseggio L, Sujobert P, Huet S, et al
    Exome sequencing identifies recurrent BCOR gene alterations and the absence of KLF2, TNFAIP3 and MYD88 mutations in splenic diffuse red pulp small B-cell lymphoma.
    Haematologica. 2017 Jul 27. pii: haematol.2016.160192.
    PubMed     Text format     Abstract available


  129. JAIS JP, Molina TJ, Ruminy P, Gentien D, et al
    Reliable subtype classification of diffuse large B-Cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assay.
    Haematologica. 2017 Jul 4. pii: haematol.2017.166827.
    PubMed     Text format    


  130. FERRERO S, Dreyling M
    Minimal residual disease in mantle cell lymphoma: are we ready for a personalized treatment approach?
    Haematologica. 2017;102:1133-1136.
    PubMed     Text format    


    June 2017
  131. VAN DE KROGT JA, Vanden Bempt M, Finalet Ferreiro J, Mentens N, et al
    ALK-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene.
    Haematologica. 2017 Jun 28. pii: haematol.2016.146571.
    PubMed     Text format     Abstract available


  132. EHRENTRAUT S, Nagel S, Pommerenke C, Dirks WG, et al
    Peripheral T-cell lymphoma cell line T8ML-1 highlights conspicuous targeting of PVRL2 by t(14;19)(q11.2;q13.3).
    Haematologica. 2017 Jun 28. pii: haematol.2017.168203.
    PubMed     Text format    


  133. BRON D, Aurer I, Andre MPE, Bonnet C, et al
    Unmet needs in the scientific approach to older patients with lymphoma.
    Haematologica. 2017;102:972-975.
    PubMed     Text format    


    May 2017
  134. CAMPOS-MARTIN Y, Martinez N, Martinez-Lopez A, Cereceda L, et al
    Clinical and diagnostic relevance of NOTCH2 and KLF2 mutations in splenic marginal zone lymphoma.
    Haematologica. 2017 May 18. pii: haematol.2016.161711.
    PubMed     Text format    


  135. DAVID A, Arnaud N, Fradet M, Lascaux H, et al
    c-Myc dysregulation is a co-transforming event for nuclear factor-kappaB activated B cells.
    Haematologica. 2017;102:883-894.
    PubMed     Text format     Abstract available


    April 2017
  136. STEVENS WBC, Mendeville M, Redd R, Clear AJ, et al
    Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: A study by the Lunenburg Lymphoma Biomarker Consortium.
    Haematologica. 2017 Apr 14. pii: haematol.2017.165415.
    PubMed     Text format     Abstract available


  137. NOBLE RA, Bell N, Blair H, Sikka A, et al
    Inhibition of monocarboxylate transporter 1 by AZD3965 as a novel therapeutic approach for the treatment of diffuse large B-cell lymphoma and Burkitt lymphoma.
    Haematologica. 2017 Apr 6. pii: haematol.2016.163030.
    PubMed     Text format     Abstract available


  138. BI C, Zhang X, Lu T, Zhang X, et al
    Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas.
    Haematologica. 2017;102:755-764.
    PubMed     Text format     Abstract available


    March 2017
  139. FUJI S, Yamaguchi T, Inoue Y, Utsunomiya A, et al
    Development of a modified prognostic index of patients with aggressive adult T-cell leukemia-lymphoma aged 70 years or younger: a possible risk-adapted management strategies including allogeneic transplantation.
    Haematologica. 2017 Mar 24. pii: haematol.2017.164996.
    PubMed     Text format     Abstract available


  140. DENG AL, Kim YR, Lichtenstein EA, O'Connor OA, et al
    Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B cell lymphoma leg type with mutant MYD88 and wildtype CD79.
    Haematologica. 2017 Mar 24. pii: haematol.2016.161893.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: